315 related articles for article (PubMed ID: 21756323)
1. Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study.
Hanefeld M; Pfützner A; Forst T; Kleine I; Fuchs W
Cardiovasc Diabetol; 2011 Jul; 10():65. PubMed ID: 21756323
[TBL] [Abstract][Full Text] [Related]
2. Effects of pioglitazone and metformin fixed-dose combination therapy on cardiovascular risk markers of inflammation and lipid profile compared with pioglitazone and metformin monotherapy in patients with type 2 diabetes.
Perez A; Jacks R; Arora V; Spanheimer R
J Clin Hypertens (Greenwich); 2010 Dec; 12(12):973-82. PubMed ID: 21122063
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of therapy with metformin plus pioglitazone in the treatment of patients with type 2 diabetes: a double-blind, placebo-controlled, clinical trial.
Kaku K
Curr Med Res Opin; 2009 May; 25(5):1111-9. PubMed ID: 19309251
[TBL] [Abstract][Full Text] [Related]
4. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study.
Mattoo V; Eckland D; Widel M; Duran S; Fajardo C; Strand J; Knight D; Grossman L; Oakley D; Tan M;
Clin Ther; 2005 May; 27(5):554-67. PubMed ID: 15978304
[TBL] [Abstract][Full Text] [Related]
5. Earlier triple therapy with pioglitazone in patients with type 2 diabetes.
Charpentier G; Halimi S;
Diabetes Obes Metab; 2009 Sep; 11(9):844-54. PubMed ID: 19614944
[TBL] [Abstract][Full Text] [Related]
6. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
[TBL] [Abstract][Full Text] [Related]
7. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
[TBL] [Abstract][Full Text] [Related]
8. Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.
Bolli G; Dotta F; Colin L; Minic B; Goodman M
Diabetes Obes Metab; 2009 Jun; 11(6):589-95. PubMed ID: 19515179
[TBL] [Abstract][Full Text] [Related]
9. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes.
Charbonnel B; Schernthaner G; Brunetti P; Matthews DR; Urquhart R; Tan MH; Hanefeld M
Diabetologia; 2005 Jun; 48(6):1093-104. PubMed ID: 15889234
[TBL] [Abstract][Full Text] [Related]
11. Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts).
Raskin P; Matfin G; Schwartz SL; Chaykin L; Chu PL; Braceras R; Wynne A
Diabetes Obes Metab; 2009 Jan; 11(1):27-32. PubMed ID: 17941873
[TBL] [Abstract][Full Text] [Related]
12. A multicentre, double-blind, placebo-controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add-on therapy in type 2 diabetic patients treated with metformin and dapagliflozin.
Lim S; Lee SH; Min KW; Lee CB; Kim SY; Yoo HJ; Kim NH; Kim JH; Oh S; Won JC; Kwon HS; Kim MK; Park JH; Jeong IK; Kim S
Diabetes Obes Metab; 2024 Jun; 26(6):2188-2198. PubMed ID: 38425186
[TBL] [Abstract][Full Text] [Related]
13. Reductions in biomarkers of cardiovascular risk in type 2 diabetes with rosiglitazone added to metformin compared with dose escalation of metformin: an EMPIRE trial sub-study.
Goldstein BJ; Weissman PN; Wooddell MJ; Waterhouse BR; Cobitz AR
Curr Med Res Opin; 2006 Sep; 22(9):1715-23. PubMed ID: 16968575
[TBL] [Abstract][Full Text] [Related]
14. Pioglitazone is effective therapy for elderly patients with type 2 diabetes mellitus.
Rajagopalan R; Perez A; Ye Z; Khan M; Murray FT
Drugs Aging; 2004; 21(4):259-71. PubMed ID: 15012171
[TBL] [Abstract][Full Text] [Related]
15. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
Roberts VL; Stewart J; Issa M; Lake B; Melis R
Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
[TBL] [Abstract][Full Text] [Related]
16. Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy.
Berhanu P; Perez A; Yu S
Diabetes Obes Metab; 2007 Jul; 9(4):512-20. PubMed ID: 17587394
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus.
Herz M; Johns D; Reviriego J; Grossman LD; Godin C; Duran S; Hawkins F; Lochnan H; Escobar-Jiménez F; Hardin PA; Konkoy CS; Tan MH
Clin Ther; 2003 Apr; 25(4):1074-95. PubMed ID: 12809958
[TBL] [Abstract][Full Text] [Related]
18. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.
Hanefeld M; Brunetti P; Schernthaner GH; Matthews DR; Charbonnel BH;
Diabetes Care; 2004 Jan; 27(1):141-7. PubMed ID: 14693980
[TBL] [Abstract][Full Text] [Related]
19. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
Buse JB; Bergenstal RM; Glass LC; Heilmann CR; Lewis MS; Kwan AY; Hoogwerf BJ; Rosenstock J
Ann Intern Med; 2011 Jan; 154(2):103-12. PubMed ID: 21138825
[TBL] [Abstract][Full Text] [Related]
20. Long-term effects of pioglitazone and metformin on insulin sensitivity in patients with Type 2 diabetes mellitus.
Roden M; Laakso M; Johns D; Widel M; Urquhart R; Richardson C; Mariz S; Tan MH
Diabet Med; 2005 Aug; 22(8):1101-6. PubMed ID: 16026380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]